From labor disputes cases to labor and employment publications, for your research, you’ll find solutions on Bloomberg Law®. Protect your clients by developing strategies based on Litigation...
Oct. 13 — Pharmaceutical manufacturer Hospira Inc. has agreed to pay $400,000 to settle allegations by the Office of Federal Contract Compliance Programs that the company violated Executive Order 11,246 by discriminating against 145 female applicants in hiring for pharmacy attendant positions in Kansas, the DOL announced.
During a scheduled compliance review, the OFCCP analyzed Hospira's 2012 hiring process and selection procedures at its McPherson, Kan., facility and found a “statistically significant disparity” in the hiring of pharmaceutical attendants based on sex, a Department of Labor spokeswoman Oct. 13 told Bloomberg BNA.
The spokeswoman said 160 females applied for the positions and 15, or 9.4 percent, were hired. By comparison, 199 males applied for the same positions and 45, or 22.6 percent, were hired, she said.
“This resulted in a hiring shortfall of 11 females and a disparity that was statistically significant at 3.34 standard deviations,” she said.
Generally, when the OFCCP conducts statistical analyses of contractors' hiring data, a finding of two or more standard deviations indicates a significant disparity in selection rates.
Hospira also failed to implement an applicant tracking system that would have allowed it to analyze the pool of applicants and monitor whether the process was “yielding an adequate pool of qualified minority applicants,” the spokeswoman said. The tracking system would also have enabled the employer to “monitor for disparate treatment or unlawful adverse impact in the selection,” she said.
Under a conciliation agreement with the OFCCP, Hospira has agreed to hire 11 female class members in addition to paying $400,000 in back wages and interest.
Hospira, which is owned by Pfizer Inc., has received more than $35 million in federal contracts to develop and manufacture injection medications for the federal government, according to the DOL.
A Pfizer spokeswoman Oct. 13 told Bloomberg BNA that Hospira believes its hiring practices at the plant have been fair.
“Hospira has a strong track record of compliance with OFCCP requirements and is confident our hiring practices support the company's priority of employing diverse and skilled talent,” she said.
To contact the reporter on this story: Jay-Anne Casuga in Washington at firstname.lastname@example.org.
To contact the editor responsible for this story: Susan J. McGolrick at email@example.com.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)